Abstract
BackgroundIn Egypt, the prevalence of hepatitis C virus infection is high (about 20%). Chronic hepatitis C (CHC) is a slowly progressive disease complicated by liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Treatment of CHC with pegylated interferon-α (peg-IFN-α)/ribavirin (R
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
